ClinOne is a technology provider of adaptive experiences in clinical trials, and it says it platform was built so it can be easily configured for protocol. It says it makes it easier for patients, caregivers, and sites to actively participate in trials.
A leading provider of adaptive experiences in clinical trials announced today it closed a $3 million series A funding to accelerate the growth of its platform and broaden its reach to serve customers.
This latest round, led by Boulder Ventures, with participation from existing investors CU Healthcare Innovation Fund and First Trust Capital Partners.
As part of this investment, ClinOne Board welcomes a new member to its board, Robert Conway who will sit as executive chair. Bob served as the chief executive officer of Array BioPharma, Inc 1999 – 2012. He serves as the chairman of ARCA, Biopharma and is on the board of directors of Signant Health and Alpine Immune Sciences.
“We are thrilled to partner with Boulder Ventures to expand ClinOne’s reach in offering high-quality, rapidly deployed solutions for clinical trials,” said Andrea Valente, CEO at ClinOne.
“Bob and I worked together at eRT, and it will be rewarding to work with him again and leverage his experience. We are proud of the work we are doing in partnership with our clients to make clinical trial participation easier for patients. Earning their collective trust is what we strive to achieve.”
ClinOne sells an integrated platform that offers support for sites, participants, and caregivers throughout the clinical trial journey. From its trial awareness module for healthcare provider engagement to patient ride, consent management, communities, and medication adherence, its cloud-based, no-code, multi-tenant platform provides an environment for rapid, efficient deployment and use.
Bob Conway said: “The most significant opportunity to improve the clinical trial process is the ‘last mile’ serving sites and patients. ClinOne has built a platform which offers ease of use along with comprehensiveness and efficiency for all stakeholders to meet. Andrea has assembled a team with deep experience to realize these goals.”
“As longtime investors in the development of new drugs, ClinOne was a natural fit for us,” said Kyle Lefkoff, general partner, and founder of Boulder Ventures.
“Participating in a pharmaceutical clinical trial is an act of conspicuous bravery by patients. ClinOne makes their participation in clinical trials simple, reliable, and useful, and by offering flexibility, can reach a diverse group of participants. ClinOne plays an important role in making clinical trials experiences better for patients.”